| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 66 | 2023 | 142 | 10.480 |
Why?
|
| Adenocarcinoma | 41 | 2020 | 189 | 5.500 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 27 | 2020 | 290 | 2.960 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 14 | 2023 | 67 | 2.870 |
Why?
|
| Chemotherapy, Adjuvant | 26 | 2020 | 75 | 2.390 |
Why?
|
| Chemoradiotherapy | 11 | 2019 | 67 | 2.000 |
Why?
|
| Radiation Oncology | 10 | 2023 | 17 | 1.980 |
Why?
|
| Fluorouracil | 21 | 2015 | 75 | 1.920 |
Why?
|
| Combined Modality Therapy | 48 | 2017 | 364 | 1.880 |
Why?
|
| Sarcoma | 7 | 2019 | 65 | 1.630 |
Why?
|
| Pancreaticoduodenectomy | 21 | 2010 | 27 | 1.610 |
Why?
|
| Brain Neoplasms | 10 | 2023 | 124 | 1.570 |
Why?
|
| Radiotherapy, Adjuvant | 24 | 2014 | 62 | 1.460 |
Why?
|
| Deoxycytidine | 15 | 2020 | 31 | 1.430 |
Why?
|
| Neoadjuvant Therapy | 9 | 2022 | 53 | 1.420 |
Why?
|
| Antimetabolites, Antineoplastic | 13 | 2012 | 26 | 1.270 |
Why?
|
| Humans | 153 | 2023 | 29337 | 1.250 |
Why?
|
| Radiotherapy, Intensity-Modulated | 7 | 2023 | 33 | 1.160 |
Why?
|
| Radiotherapy Dosage | 22 | 2023 | 113 | 1.070 |
Why?
|
| Antineoplastic Agents | 14 | 2013 | 218 | 1.050 |
Why?
|
| Radiotherapy, Conformal | 4 | 2023 | 19 | 0.950 |
Why?
|
| Organs at Risk | 7 | 2016 | 15 | 0.900 |
Why?
|
| Adult | 69 | 2020 | 8601 | 0.900 |
Why?
|
| Middle Aged | 79 | 2020 | 9823 | 0.890 |
Why?
|
| Aged | 70 | 2022 | 9448 | 0.850 |
Why?
|
| Survival Analysis | 29 | 2019 | 298 | 0.850 |
Why?
|
| Tumor Burden | 11 | 2017 | 28 | 0.840 |
Why?
|
| Treatment Outcome | 35 | 2019 | 3478 | 0.830 |
Why?
|
| Male | 86 | 2021 | 15621 | 0.820 |
Why?
|
| Female | 82 | 2021 | 16197 | 0.800 |
Why?
|
| Liver Neoplasms | 9 | 2016 | 103 | 0.790 |
Why?
|
| Radiometry | 4 | 2012 | 38 | 0.780 |
Why?
|
| Radiosurgery | 4 | 2023 | 33 | 0.760 |
Why?
|
| Prognosis | 24 | 2020 | 840 | 0.740 |
Why?
|
| CA-19-9 Antigen | 6 | 2017 | 6 | 0.650 |
Why?
|
| Carcinoma, Hepatocellular | 5 | 2000 | 32 | 0.640 |
Why?
|
| Bone Marrow Transplantation | 10 | 2005 | 34 | 0.630 |
Why?
|
| Pancreatectomy | 3 | 2016 | 10 | 0.630 |
Why?
|
| Clinical Trials as Topic | 8 | 2010 | 324 | 0.620 |
Why?
|
| Lung Neoplasms | 11 | 2011 | 625 | 0.620 |
Why?
|
| Glioma | 5 | 2020 | 47 | 0.610 |
Why?
|
| Ampulla of Vater | 4 | 2008 | 6 | 0.590 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2014 | 24 | 0.590 |
Why?
|
| Attention | 5 | 2000 | 144 | 0.570 |
Why?
|
| Common Bile Duct Neoplasms | 3 | 2007 | 3 | 0.550 |
Why?
|
| Medical Illustration | 2 | 2012 | 20 | 0.510 |
Why?
|
| Algorithms | 7 | 2015 | 400 | 0.510 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 5 | 2011 | 316 | 0.500 |
Why?
|
| Radiation Injuries | 4 | 2023 | 34 | 0.500 |
Why?
|
| Lymphoma, Non-Hodgkin | 4 | 2005 | 42 | 0.490 |
Why?
|
| Brachytherapy | 3 | 2016 | 47 | 0.490 |
Why?
|
| Retrospective Studies | 25 | 2021 | 3273 | 0.490 |
Why?
|
| Aged, 80 and over | 28 | 2020 | 4851 | 0.470 |
Why?
|
| Hodgkin Disease | 4 | 2003 | 19 | 0.470 |
Why?
|
| Breast Neoplasms | 4 | 2014 | 329 | 0.470 |
Why?
|
| Cholangiocarcinoma | 4 | 2009 | 12 | 0.460 |
Why?
|
| Survival Rate | 23 | 2017 | 349 | 0.440 |
Why?
|
| Evidence-Based Medicine | 3 | 2016 | 208 | 0.440 |
Why?
|
| Quality Assurance, Health Care | 4 | 2016 | 49 | 0.430 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2011 | 16 | 0.430 |
Why?
|
| Whole-Body Irradiation | 5 | 2012 | 18 | 0.430 |
Why?
|
| Bile Duct Neoplasms | 4 | 2009 | 12 | 0.420 |
Why?
|
| Bile Ducts, Intrahepatic | 3 | 2009 | 7 | 0.420 |
Why?
|
| Disease-Free Survival | 16 | 2017 | 175 | 0.410 |
Why?
|
| Retroperitoneal Neoplasms | 3 | 2015 | 7 | 0.400 |
Why?
|
| Guideline Adherence | 2 | 2011 | 67 | 0.400 |
Why?
|
| Supratentorial Neoplasms | 4 | 2011 | 6 | 0.400 |
Why?
|
| Radiation-Sensitizing Agents | 4 | 2014 | 10 | 0.390 |
Why?
|
| Duodenal Neoplasms | 4 | 2007 | 7 | 0.370 |
Why?
|
| Cranial Irradiation | 1 | 2010 | 12 | 0.370 |
Why?
|
| Limbic System | 1 | 2010 | 11 | 0.370 |
Why?
|
| Proportional Hazards Models | 12 | 2021 | 340 | 0.360 |
Why?
|
| Holography | 1 | 2009 | 2 | 0.360 |
Why?
|
| Cisplatin | 4 | 2010 | 91 | 0.350 |
Why?
|
| Radiotherapy | 7 | 2005 | 50 | 0.340 |
Why?
|
| Carcinoma, Small Cell | 6 | 2005 | 71 | 0.330 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2009 | 81 | 0.330 |
Why?
|
| Chemoradiotherapy, Adjuvant | 3 | 2014 | 16 | 0.330 |
Why?
|
| Neoplasm Staging | 15 | 2017 | 340 | 0.320 |
Why?
|
| Employment | 2 | 2018 | 42 | 0.310 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2009 | 222 | 0.310 |
Why?
|
| Prospective Studies | 18 | 2022 | 1811 | 0.310 |
Why?
|
| Electronics | 1 | 2007 | 9 | 0.310 |
Why?
|
| Visual Perception | 2 | 2000 | 50 | 0.300 |
Why?
|
| Gastrointestinal Neoplasms | 3 | 2003 | 14 | 0.300 |
Why?
|
| Lymphatic Metastasis | 8 | 2015 | 81 | 0.300 |
Why?
|
| Rectal Neoplasms | 2 | 2021 | 19 | 0.290 |
Why?
|
| Practice Guidelines as Topic | 4 | 2017 | 333 | 0.290 |
Why?
|
| Tomography, X-Ray Computed | 8 | 2016 | 770 | 0.280 |
Why?
|
| Radiology | 2 | 2016 | 22 | 0.280 |
Why?
|
| Cyclophosphamide | 5 | 2003 | 55 | 0.280 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2011 | 184 | 0.280 |
Why?
|
| Doxorubicin | 6 | 2019 | 45 | 0.280 |
Why?
|
| Biomarkers, Tumor | 5 | 2010 | 175 | 0.280 |
Why?
|
| Astrocytoma | 3 | 2020 | 24 | 0.280 |
Why?
|
| Multivariate Analysis | 8 | 2015 | 324 | 0.270 |
Why?
|
| Maximum Tolerated Dose | 2 | 2012 | 16 | 0.270 |
Why?
|
| Cancer Vaccines | 4 | 2011 | 10 | 0.250 |
Why?
|
| Time Factors | 10 | 2017 | 1616 | 0.250 |
Why?
|
| Brain Injuries | 1 | 2023 | 47 | 0.230 |
Why?
|
| Orientation | 2 | 1995 | 10 | 0.230 |
Why?
|
| Follow-Up Studies | 11 | 2018 | 1830 | 0.230 |
Why?
|
| Celiac Plexus | 1 | 2022 | 2 | 0.220 |
Why?
|
| Cardiac Volume | 1 | 2022 | 5 | 0.220 |
Why?
|
| Cancer Pain | 1 | 2022 | 4 | 0.220 |
Why?
|
| Fixation, Ocular | 3 | 2000 | 8 | 0.220 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2022 | 18 | 0.210 |
Why?
|
| Carcinoid Tumor | 2 | 1995 | 8 | 0.210 |
Why?
|
| Analysis of Variance | 7 | 2018 | 321 | 0.210 |
Why?
|
| Lymphoma, Mantle-Cell | 3 | 2009 | 6 | 0.210 |
Why?
|
| Radioimmunotherapy | 3 | 2003 | 4 | 0.210 |
Why?
|
| Consensus | 4 | 2016 | 105 | 0.200 |
Why?
|
| Saccades | 3 | 1998 | 3 | 0.200 |
Why?
|
| Dose-Response Relationship, Radiation | 4 | 2007 | 16 | 0.200 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2021 | 162 | 0.200 |
Why?
|
| Eye Movements | 3 | 2000 | 20 | 0.190 |
Why?
|
| Insulins | 1 | 2020 | 4 | 0.190 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 3 | 2011 | 22 | 0.190 |
Why?
|
| Reproducibility of Results | 5 | 2015 | 788 | 0.190 |
Why?
|
| Palliative Care | 5 | 2004 | 145 | 0.190 |
Why?
|
| Disease Progression | 10 | 2012 | 787 | 0.190 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2020 | 16 | 0.190 |
Why?
|
| Immunotherapy | 3 | 2011 | 62 | 0.180 |
Why?
|
| United States | 7 | 2018 | 2333 | 0.180 |
Why?
|
| Lymph Nodes | 2 | 2010 | 70 | 0.180 |
Why?
|
| Neoplasms | 3 | 2003 | 247 | 0.170 |
Why?
|
| Mesna | 1 | 2019 | 3 | 0.170 |
Why?
|
| Ifosfamide | 1 | 2019 | 8 | 0.170 |
Why?
|
| Organ Sparing Treatments | 1 | 2019 | 7 | 0.170 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 138 | 0.170 |
Why?
|
| Prostatic Neoplasms | 4 | 2003 | 106 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2012 | 340 | 0.170 |
Why?
|
| Lymphoma | 3 | 2009 | 44 | 0.170 |
Why?
|
| Career Choice | 1 | 2018 | 30 | 0.170 |
Why?
|
| Leg | 1 | 2019 | 49 | 0.170 |
Why?
|
| Breast | 2 | 2009 | 16 | 0.170 |
Why?
|
| Radiography | 4 | 2015 | 678 | 0.170 |
Why?
|
| Arm | 1 | 2019 | 78 | 0.170 |
Why?
|
| alpha-Fetoproteins | 1 | 1998 | 5 | 0.170 |
Why?
|
| Patient Selection | 4 | 2017 | 232 | 0.160 |
Why?
|
| Iodine Radioisotopes | 1 | 1998 | 16 | 0.160 |
Why?
|
| Research Design | 3 | 2009 | 212 | 0.160 |
Why?
|
| Pitch Discrimination | 1 | 1998 | 2 | 0.160 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2012 | 23 | 0.160 |
Why?
|
| Chi-Square Distribution | 5 | 2018 | 145 | 0.160 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2012 | 25 | 0.160 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2017 | 9 | 0.160 |
Why?
|
| Arousal | 1 | 1998 | 42 | 0.160 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 2017 | 6 | 0.160 |
Why?
|
| Lymphocytes | 1 | 2018 | 110 | 0.160 |
Why?
|
| Sensitivity and Specificity | 3 | 2012 | 553 | 0.160 |
Why?
|
| Digestive System Neoplasms | 1 | 1997 | 5 | 0.160 |
Why?
|
| Neutrophils | 1 | 2018 | 117 | 0.150 |
Why?
|
| Preoperative Care | 4 | 2015 | 135 | 0.150 |
Why?
|
| Databases, Factual | 3 | 2021 | 330 | 0.150 |
Why?
|
| Reaction Time | 5 | 2000 | 123 | 0.150 |
Why?
|
| Stomach | 2 | 2015 | 18 | 0.140 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2016 | 5 | 0.140 |
Why?
|
| Quality of Life | 3 | 2015 | 662 | 0.140 |
Why?
|
| Hepatectomy | 2 | 2015 | 55 | 0.140 |
Why?
|
| Intestine, Small | 2 | 2015 | 33 | 0.140 |
Why?
|
| RecQ Helicases | 1 | 2015 | 1 | 0.140 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2015 | 12 | 0.140 |
Why?
|
| Adolescent | 10 | 2011 | 2279 | 0.140 |
Why?
|
| Polymorphism, Genetic | 1 | 2015 | 78 | 0.130 |
Why?
|
| Liposarcoma | 1 | 2015 | 5 | 0.130 |
Why?
|
| Color Perception | 1 | 1995 | 6 | 0.130 |
Why?
|
| Risk Factors | 8 | 2015 | 2443 | 0.130 |
Why?
|
| Neoplasm Metastasis | 4 | 2014 | 101 | 0.130 |
Why?
|
| Animals | 3 | 2014 | 4552 | 0.130 |
Why?
|
| Postoperative Care | 4 | 2008 | 127 | 0.130 |
Why?
|
| Liver | 2 | 2012 | 173 | 0.130 |
Why?
|
| Mental Recall | 1 | 1995 | 74 | 0.130 |
Why?
|
| Receptor, ErbB-2 | 1 | 2014 | 41 | 0.120 |
Why?
|
| Neural Inhibition | 1 | 1994 | 10 | 0.120 |
Why?
|
| History, 21st Century | 1 | 2014 | 36 | 0.120 |
Why?
|
| Health Status | 1 | 2015 | 227 | 0.120 |
Why?
|
| History, 20th Century | 1 | 2014 | 84 | 0.120 |
Why?
|
| Pancreaticojejunostomy | 2 | 2012 | 3 | 0.120 |
Why?
|
| Internship and Residency | 1 | 2017 | 211 | 0.120 |
Why?
|
| Paclitaxel | 4 | 2011 | 74 | 0.120 |
Why?
|
| Extremities | 1 | 2013 | 31 | 0.110 |
Why?
|
| Edema | 1 | 2013 | 38 | 0.110 |
Why?
|
| France | 1 | 2012 | 37 | 0.110 |
Why?
|
| Celiac Artery | 1 | 2012 | 2 | 0.110 |
Why?
|
| Mesenteric Artery, Superior | 1 | 2012 | 4 | 0.110 |
Why?
|
| Aortography | 1 | 2012 | 10 | 0.110 |
Why?
|
| Radiography, Abdominal | 1 | 2012 | 6 | 0.110 |
Why?
|
| Anatomic Landmarks | 1 | 2012 | 7 | 0.110 |
Why?
|
| Lymph Node Excision | 3 | 2010 | 26 | 0.110 |
Why?
|
| Portal Vein | 1 | 2012 | 40 | 0.100 |
Why?
|
| Spinal Cord | 1 | 2012 | 103 | 0.100 |
Why?
|
| Capecitabine | 3 | 2017 | 6 | 0.100 |
Why?
|
| Ossification, Heterotopic | 1 | 2011 | 42 | 0.100 |
Why?
|
| Cohort Studies | 5 | 2017 | 1939 | 0.100 |
Why?
|
| Kidney | 1 | 2012 | 173 | 0.100 |
Why?
|
| Transplantation, Homologous | 6 | 2005 | 277 | 0.100 |
Why?
|
| Transplantation, Autologous | 5 | 2009 | 195 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 2 | 2009 | 260 | 0.100 |
Why?
|
| Distance Perception | 1 | 1990 | 1 | 0.090 |
Why?
|
| Optical Illusions | 1 | 1990 | 1 | 0.090 |
Why?
|
| Pancreatitis, Chronic | 1 | 2010 | 1 | 0.090 |
Why?
|
| Form Perception | 1 | 1990 | 2 | 0.090 |
Why?
|
| Illusions | 1 | 1990 | 4 | 0.090 |
Why?
|
| Motion Perception | 1 | 1990 | 2 | 0.090 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2010 | 11 | 0.090 |
Why?
|
| Weight Gain | 1 | 2010 | 66 | 0.090 |
Why?
|
| Multicenter Studies as Topic | 3 | 2010 | 75 | 0.090 |
Why?
|
| Elbow Joint | 1 | 2011 | 131 | 0.090 |
Why?
|
| Immune System | 1 | 2009 | 20 | 0.090 |
Why?
|
| Pilot Projects | 2 | 2023 | 394 | 0.090 |
Why?
|
| DNA, Neoplasm | 2 | 2003 | 25 | 0.090 |
Why?
|
| Mastectomy, Segmental | 1 | 2009 | 13 | 0.090 |
Why?
|
| Maryland | 2 | 2007 | 8 | 0.090 |
Why?
|
| Stem Cell Transplantation | 1 | 2009 | 40 | 0.090 |
Why?
|
| Feasibility Studies | 1 | 2010 | 227 | 0.090 |
Why?
|
| Statistics, Nonparametric | 2 | 2015 | 138 | 0.090 |
Why?
|
| Equilibrative Nucleoside Transporter 1 | 1 | 2008 | 1 | 0.090 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2014 | 24 | 0.080 |
Why?
|
| Gastrectomy | 2 | 2005 | 24 | 0.080 |
Why?
|
| Gastrointestinal Diseases | 2 | 2015 | 43 | 0.080 |
Why?
|
| Esophageal Neoplasms | 2 | 2000 | 45 | 0.080 |
Why?
|
| Recovery of Function | 1 | 2009 | 290 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 1997 | 178 | 0.080 |
Why?
|
| Orthopedic Procedures | 1 | 2011 | 317 | 0.080 |
Why?
|
| Neuroectodermal Tumors, Primitive, Peripheral | 1 | 1987 | 1 | 0.080 |
Why?
|
| Hippocampus | 1 | 2010 | 274 | 0.080 |
Why?
|
| Baltimore | 2 | 2004 | 14 | 0.080 |
Why?
|
| Plasmacytoma | 1 | 1987 | 18 | 0.080 |
Why?
|
| Hemibody Irradiation | 1 | 2007 | 2 | 0.080 |
Why?
|
| Iridium Radioisotopes | 1 | 2007 | 3 | 0.080 |
Why?
|
| Radiotherapy, High-Energy | 3 | 1997 | 7 | 0.080 |
Why?
|
| Graft vs Host Disease | 4 | 2001 | 45 | 0.080 |
Why?
|
| Incidence | 1 | 2010 | 756 | 0.080 |
Why?
|
| Cues | 2 | 2000 | 61 | 0.080 |
Why?
|
| Hospitals, University | 2 | 2004 | 39 | 0.080 |
Why?
|
| Nose Neoplasms | 1 | 1987 | 34 | 0.070 |
Why?
|
| Induction Chemotherapy | 2 | 2017 | 14 | 0.070 |
Why?
|
| Heart | 1 | 2007 | 91 | 0.070 |
Why?
|
| Leukemia | 1 | 1986 | 10 | 0.070 |
Why?
|
| Risk Assessment | 2 | 2011 | 679 | 0.070 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2000 | 219 | 0.070 |
Why?
|
| Lung | 1 | 2007 | 154 | 0.070 |
Why?
|
| Pancreas | 2 | 2015 | 32 | 0.070 |
Why?
|
| Etoposide | 4 | 2011 | 48 | 0.070 |
Why?
|
| Hematopoietic Stem Cells | 2 | 1985 | 13 | 0.070 |
Why?
|
| Drug Administration Schedule | 3 | 2015 | 223 | 0.070 |
Why?
|
| Phantoms, Imaging | 1 | 2005 | 42 | 0.070 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2005 | 3 | 0.070 |
Why?
|
| Observer Variation | 2 | 2015 | 118 | 0.070 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2005 | 13 | 0.060 |
Why?
|
| Societies, Medical | 2 | 2017 | 190 | 0.060 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2004 | 6 | 0.060 |
Why?
|
| Equipment Failure Analysis | 1 | 2005 | 106 | 0.060 |
Why?
|
| Equipment Design | 1 | 2005 | 185 | 0.060 |
Why?
|
| Surveys and Questionnaires | 3 | 2018 | 1184 | 0.060 |
Why?
|
| Mitomycin | 2 | 2001 | 12 | 0.060 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2004 | 19 | 0.060 |
Why?
|
| Bacteria, Anaerobic | 1 | 2003 | 1 | 0.060 |
Why?
|
| Cognition | 2 | 2020 | 1277 | 0.060 |
Why?
|
| Leukocyte Count | 3 | 2018 | 92 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2003 | 22 | 0.060 |
Why?
|
| Hypoxia | 1 | 2003 | 60 | 0.060 |
Why?
|
| Diploidy | 1 | 2003 | 4 | 0.060 |
Why?
|
| Androgen Antagonists | 1 | 2003 | 4 | 0.060 |
Why?
|
| Flutamide | 3 | 2003 | 3 | 0.060 |
Why?
|
| Goserelin | 3 | 2003 | 3 | 0.060 |
Why?
|
| Drug Therapy | 1 | 2003 | 16 | 0.060 |
Why?
|
| Cyclosporine | 2 | 1999 | 15 | 0.060 |
Why?
|
| Delphi Technique | 1 | 2022 | 27 | 0.050 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2003 | 132 | 0.050 |
Why?
|
| Respiration | 1 | 2022 | 35 | 0.050 |
Why?
|
| Europe | 1 | 2001 | 81 | 0.050 |
Why?
|
| Brain | 2 | 2023 | 1689 | 0.050 |
Why?
|
| Blood Transfusion | 1 | 2001 | 64 | 0.050 |
Why?
|
| Clinical Protocols | 2 | 1998 | 65 | 0.050 |
Why?
|
| Crohn Disease | 1 | 2001 | 46 | 0.050 |
Why?
|
| Treatment Failure | 2 | 1999 | 159 | 0.050 |
Why?
|
| Blood Platelets | 2 | 1997 | 49 | 0.050 |
Why?
|
| Professional Staff Committees | 1 | 2001 | 9 | 0.050 |
Why?
|
| Hematopoiesis | 1 | 1981 | 11 | 0.050 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2001 | 14 | 0.050 |
Why?
|
| Colitis, Ulcerative | 1 | 2001 | 66 | 0.050 |
Why?
|
| Anastomosis, Surgical | 2 | 1997 | 34 | 0.050 |
Why?
|
| Marital Status | 1 | 2019 | 15 | 0.050 |
Why?
|
| Patient Care Planning | 1 | 2000 | 56 | 0.050 |
Why?
|
| Colonic Neoplasms | 1 | 2000 | 66 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 1999 | 109 | 0.040 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 1999 | 4 | 0.040 |
Why?
|
| Population Density | 1 | 2018 | 7 | 0.040 |
Why?
|
| Cities | 1 | 2018 | 14 | 0.040 |
Why?
|
| Job Application | 1 | 2018 | 6 | 0.040 |
Why?
|
| Schools, Medical | 1 | 2018 | 22 | 0.040 |
Why?
|
| Antigens, CD34 | 1 | 1998 | 14 | 0.040 |
Why?
|
| Hematologic Neoplasms | 1 | 1998 | 17 | 0.040 |
Why?
|
| Consumer Behavior | 1 | 2018 | 20 | 0.040 |
Why?
|
| AIDS Dementia Complex | 1 | 1999 | 41 | 0.040 |
Why?
|
| Regression Analysis | 2 | 2012 | 298 | 0.040 |
Why?
|
| HIV Seropositivity | 1 | 1999 | 94 | 0.040 |
Why?
|
| Psychophysics | 1 | 1998 | 5 | 0.040 |
Why?
|
| Sound Localization | 1 | 1998 | 7 | 0.040 |
Why?
|
| Infusions, Intra-Arterial | 1 | 1997 | 2 | 0.040 |
Why?
|
| Necrosis | 1 | 2017 | 26 | 0.040 |
Why?
|
| Remission Induction | 2 | 2010 | 96 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 1998 | 89 | 0.040 |
Why?
|
| Genetic Therapy | 1 | 1998 | 89 | 0.040 |
Why?
|
| Vincristine | 3 | 2000 | 26 | 0.040 |
Why?
|
| Mental Status Schedule | 2 | 2011 | 113 | 0.040 |
Why?
|
| Bone Marrow Purging | 1 | 1997 | 3 | 0.040 |
Why?
|
| Platelet Count | 1 | 1997 | 20 | 0.040 |
Why?
|
| Blood Cells | 1 | 1997 | 6 | 0.040 |
Why?
|
| Professional Practice Location | 1 | 2017 | 2 | 0.040 |
Why?
|
| Censuses | 1 | 2017 | 6 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2010 | 389 | 0.040 |
Why?
|
| Academies and Institutes | 1 | 2017 | 10 | 0.040 |
Why?
|
| Safety | 1 | 1997 | 45 | 0.040 |
Why?
|
| Esophagectomy | 1 | 1997 | 21 | 0.040 |
Why?
|
| Blood Loss, Surgical | 1 | 1997 | 64 | 0.040 |
Why?
|
| Cell Line, Tumor | 2 | 2011 | 264 | 0.040 |
Why?
|
| Hypersensitivity, Delayed | 2 | 2011 | 21 | 0.040 |
Why?
|
| ROC Curve | 1 | 2017 | 138 | 0.040 |
Why?
|
| Biopsy | 1 | 1997 | 234 | 0.040 |
Why?
|
| Neutropenia | 2 | 2012 | 21 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 1997 | 100 | 0.040 |
Why?
|
| Thrombocytopenia | 2 | 2012 | 30 | 0.040 |
Why?
|
| Cognition Disorders | 1 | 2003 | 1011 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2016 | 67 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 1997 | 89 | 0.030 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2015 | 16 | 0.030 |
Why?
|
| Pelvis | 2 | 2008 | 30 | 0.030 |
Why?
|
| Etanidazole | 1 | 1995 | 1 | 0.030 |
Why?
|
| United Kingdom | 1 | 2015 | 50 | 0.030 |
Why?
|
| Feeding and Eating Disorders | 1 | 2015 | 12 | 0.030 |
Why?
|
| Research Personnel | 1 | 2015 | 20 | 0.030 |
Why?
|
| Peritoneal Cavity | 1 | 2015 | 3 | 0.030 |
Why?
|
| Duodenum | 1 | 2015 | 12 | 0.030 |
Why?
|
| Length of Stay | 1 | 1997 | 317 | 0.030 |
Why?
|
| Actuarial Analysis | 2 | 1993 | 14 | 0.030 |
Why?
|
| Nephrectomy | 1 | 2015 | 29 | 0.030 |
Why?
|
| Benchmarking | 1 | 2015 | 41 | 0.030 |
Why?
|
| Alleles | 1 | 2015 | 224 | 0.030 |
Why?
|
| Pattern Recognition, Visual | 1 | 1995 | 31 | 0.030 |
Why?
|
| Fatigue | 1 | 2015 | 59 | 0.030 |
Why?
|
| Ethane | 1 | 1994 | 2 | 0.030 |
Why?
|
| Nucleic Acid Conformation | 1 | 1994 | 3 | 0.030 |
Why?
|
| DNA Damage | 1 | 1994 | 30 | 0.030 |
Why?
|
| Cell Division | 1 | 1994 | 113 | 0.030 |
Why?
|
| Retroperitoneal Space | 2 | 2005 | 12 | 0.030 |
Why?
|
| Genotype | 1 | 2015 | 405 | 0.030 |
Why?
|
| Portal System | 1 | 1994 | 2 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 1994 | 124 | 0.030 |
Why?
|
| Avitaminosis | 1 | 2013 | 1 | 0.030 |
Why?
|
| Dumping Syndrome | 1 | 2013 | 1 | 0.030 |
Why?
|
| Anorexia | 1 | 2013 | 4 | 0.030 |
Why?
|
| Head and Neck Neoplasms | 1 | 1995 | 133 | 0.030 |
Why?
|
| Colon | 1 | 2015 | 148 | 0.030 |
Why?
|
| Diarrhea | 1 | 2013 | 48 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2015 | 140 | 0.030 |
Why?
|
| Radioisotopes | 1 | 2013 | 13 | 0.030 |
Why?
|
| Gadolinium | 1 | 2013 | 11 | 0.030 |
Why?
|
| Radiation Effects | 1 | 1992 | 1 | 0.030 |
Why?
|
| Radiation Tolerance | 1 | 1992 | 7 | 0.030 |
Why?
|
| Reoperation | 1 | 1997 | 932 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2013 | 31 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 1113 | 0.030 |
Why?
|
| Postoperative Complications | 3 | 2011 | 957 | 0.030 |
Why?
|
| Recurrence | 2 | 2005 | 350 | 0.030 |
Why?
|
| Body Burden | 1 | 2012 | 9 | 0.030 |
Why?
|
| Cause of Death | 1 | 2012 | 65 | 0.030 |
Why?
|
| Biomarkers | 1 | 2015 | 689 | 0.030 |
Why?
|
| Gastrointestinal Tract | 1 | 2012 | 55 | 0.030 |
Why?
|
| Ocular Motility Disorders | 1 | 1991 | 3 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2003 | 391 | 0.030 |
Why?
|
| Carboplatin | 1 | 2011 | 49 | 0.030 |
Why?
|
| GPI-Linked Proteins | 1 | 2011 | 25 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2011 | 37 | 0.020 |
Why?
|
| Sex Factors | 1 | 2012 | 496 | 0.020 |
Why?
|
| Transfection | 1 | 2011 | 125 | 0.020 |
Why?
|
| Reference Standards | 1 | 2010 | 33 | 0.020 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2011 | 107 | 0.020 |
Why?
|
| Kinesthesis | 1 | 1990 | 3 | 0.020 |
Why?
|
| Validation Studies as Topic | 1 | 2010 | 4 | 0.020 |
Why?
|
| Interferon-alpha | 1 | 2010 | 66 | 0.020 |
Why?
|
| DNA | 1 | 2010 | 125 | 0.020 |
Why?
|
| Transplantation Immunology | 1 | 2009 | 2 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2010 | 251 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2011 | 211 | 0.020 |
Why?
|
| Rituximab | 1 | 2009 | 53 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2009 | 38 | 0.020 |
Why?
|
| Contracture | 1 | 2009 | 13 | 0.020 |
Why?
|
| Drug Evaluation | 2 | 1986 | 52 | 0.020 |
Why?
|
| Depression | 1 | 2013 | 465 | 0.020 |
Why?
|
| Organ Size | 1 | 2009 | 107 | 0.020 |
Why?
|
| Inguinal Canal | 1 | 2008 | 1 | 0.020 |
Why?
|
| Anus Neoplasms | 1 | 2008 | 6 | 0.020 |
Why?
|
| Likelihood Functions | 1 | 2008 | 29 | 0.020 |
Why?
|
| Child | 2 | 2005 | 1346 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2010 | 124 | 0.020 |
Why?
|
| Leucovorin | 2 | 2000 | 16 | 0.020 |
Why?
|
| Rectum | 1 | 2008 | 61 | 0.020 |
Why?
|
| Ilium | 1 | 2008 | 31 | 0.020 |
Why?
|
| Psychomotor Performance | 1 | 1990 | 216 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2008 | 323 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 1987 | 22 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 1221 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 1987 | 40 | 0.020 |
Why?
|
| Nasal Cavity | 1 | 1987 | 35 | 0.020 |
Why?
|
| Lomustine | 1 | 1986 | 2 | 0.020 |
Why?
|
| Procarbazine | 1 | 1986 | 3 | 0.020 |
Why?
|
| Methotrexate | 1 | 1986 | 41 | 0.020 |
Why?
|
| Amsacrine | 1 | 1986 | 2 | 0.020 |
Why?
|
| Aminoacridines | 1 | 1986 | 2 | 0.020 |
Why?
|
| Blood Cell Count | 1 | 1986 | 15 | 0.020 |
Why?
|
| Bone Marrow | 1 | 1986 | 73 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1986 | 437 | 0.020 |
Why?
|
| Cardiac Output | 1 | 1985 | 21 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2005 | 76 | 0.020 |
Why?
|
| Bias | 1 | 2005 | 33 | 0.020 |
Why?
|
| Transplantation Conditioning | 1 | 2005 | 35 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2005 | 66 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 1985 | 57 | 0.020 |
Why?
|
| Young Adult | 1 | 2011 | 1932 | 0.020 |
Why?
|
| Random Allocation | 1 | 1985 | 146 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2005 | 96 | 0.020 |
Why?
|
| Probability | 1 | 2005 | 94 | 0.020 |
Why?
|
| Cesium Radioisotopes | 1 | 2003 | 1 | 0.020 |
Why?
|
| Clostridium | 1 | 2003 | 3 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2003 | 23 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2003 | 42 | 0.020 |
Why?
|
| Sampling Studies | 1 | 2003 | 28 | 0.020 |
Why?
|
| HIV Infections | 1 | 1991 | 970 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 2003 | 70 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2003 | 85 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2003 | 263 | 0.010 |
Why?
|
| Cell Line | 1 | 2003 | 298 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2003 | 36 | 0.010 |
Why?
|
| Quinolones | 1 | 2003 | 21 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2005 | 642 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2003 | 145 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2003 | 432 | 0.010 |
Why?
|
| Quality of Health Care | 1 | 2003 | 138 | 0.010 |
Why?
|
| Smad4 Protein | 1 | 2001 | 2 | 0.010 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2001 | 11 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2001 | 24 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2003 | 521 | 0.010 |
Why?
|
| Lymphocyte Depletion | 1 | 2001 | 4 | 0.010 |
Why?
|
| Colony-Forming Units Assay | 1 | 1981 | 4 | 0.010 |
Why?
|
| Consumer Product Safety | 1 | 2001 | 3 | 0.010 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2001 | 11 | 0.010 |
Why?
|
| Granulocytes | 1 | 1981 | 23 | 0.010 |
Why?
|
| Dipyridamole | 1 | 2000 | 4 | 0.010 |
Why?
|
| Organizational Objectives | 1 | 2001 | 23 | 0.010 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2001 | 18 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2000 | 96 | 0.010 |
Why?
|
| Forecasting | 1 | 2001 | 117 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2003 | 724 | 0.010 |
Why?
|
| Intestinal Perforation | 1 | 2000 | 4 | 0.010 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2000 | 11 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 1981 | 241 | 0.010 |
Why?
|
| Monocytes | 1 | 1981 | 116 | 0.010 |
Why?
|
| Intestinal Fistula | 1 | 2000 | 7 | 0.010 |
Why?
|
| Colonic Diseases | 1 | 2000 | 12 | 0.010 |
Why?
|
| Radiographic Image Enhancement | 1 | 2000 | 16 | 0.010 |
Why?
|
| Intestinal Obstruction | 1 | 2000 | 12 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2000 | 68 | 0.010 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2000 | 24 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2001 | 254 | 0.010 |
Why?
|
| Prednisone | 1 | 2000 | 67 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2004 | 1251 | 0.010 |
Why?
|
| Adipose Tissue | 1 | 2000 | 73 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2001 | 482 | 0.010 |
Why?
|
| Transplantation Chimera | 1 | 1998 | 1 | 0.010 |
Why?
|
| Mice | 1 | 2003 | 1607 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 1998 | 5 | 0.010 |
Why?
|
| Morbidity | 1 | 1999 | 63 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 2000 | 101 | 0.010 |
Why?
|
| Vaccination | 1 | 1998 | 41 | 0.010 |
Why?
|
| Contraindications | 1 | 1998 | 41 | 0.010 |
Why?
|
| Graft Rejection | 1 | 1998 | 76 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 1998 | 132 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2001 | 1442 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 1997 | 33 | 0.010 |
Why?
|
| Genes, p53 | 1 | 1997 | 17 | 0.010 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 1997 | 18 | 0.010 |
Why?
|
| Gastrostomy | 1 | 1996 | 8 | 0.010 |
Why?
|
| Jejunostomy | 1 | 1996 | 6 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 1998 | 638 | 0.010 |
Why?
|
| Dexamethasone | 1 | 1996 | 48 | 0.010 |
Why?
|
| Lipid Peroxidation | 1 | 1994 | 9 | 0.010 |
Why?
|
| Free Radicals | 1 | 1994 | 9 | 0.010 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1994 | 9 | 0.010 |
Why?
|
| Breath Tests | 1 | 1994 | 11 | 0.010 |
Why?
|
| Mutation | 1 | 1997 | 383 | 0.010 |
Why?
|
| Carmustine | 1 | 1993 | 5 | 0.010 |
Why?
|
| Yttrium Radioisotopes | 1 | 1993 | 5 | 0.010 |
Why?
|
| Ferritins | 1 | 1993 | 9 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 1993 | 50 | 0.010 |
Why?
|
| Pursuit, Smooth | 1 | 1991 | 2 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1991 | 218 | 0.010 |
Why?
|